< Back to situations

Get alerts on this situation

We’ll email you as it develops, and you can follow the whole thread from day one.

Unsubscribe anytime.

[SITUATION] · [ACTIVE]

4 clusters · 20 sources · 11 days · First seen 11 days ago · Last updated about 19 hours ago

Categories: HEALTH

Sildenafil potential to inhibit cancer metastasis

Entities: Ayelet Erez · Weizmann Institute of Science · Sildenafil (Viagra) · Statins · Cancer Research

Overview

Late‑July 2026 reports from U.S. and Israeli laboratories showed that sildenafil, the active ingredient in Viagra, suppressed metastatic spread in mouse models of breast, lung, colon and prostate cancer by inhibiting PDE5, raising cGMP, and sequestering cholesterol in lysosomes. A follow‑up study from Israel’s Weizmann Institute confirmed the same biochemical pathway and demonstrated that combining sildenafil with statins further reduced metastatic potential in pre‑clinical experiments.

An analysis of health‑service records for nearly five million Israeli patients found that cancer patients prescribed sildenafil—especially when co‑prescribed with statins—had better survival outcomes than matched controls. Laboratory work with mouse and human cancer cells showed slower cholesterol transport and reduced cell migration after sildenafil treatment.

On 31 July 2026, Weizmann Institute researchers, together with U.S. collaborators, published a retrospective analysis of individuals who had taken sildenafil before cancer diagnosis. The study reaffirmed that PDE5 inhibition raises cGMP and disrupts cholesterol handling in malignant cells, impeding detachment and metastatic seeding. Experiments indicated that the anti‑metastatic effect was amplified when sildenafil was combined with statins.

A study released on 30 July 2026 in *Cancer Research*—led by Ayelet Erez and Yarden Ariav—detailed the PDE5‑cGMP‑NPC1 mechanism, showing that elevated cGMP interferes with NPC1‑mediated cholesterol transport, making highly migratory tumor cells especially vulnerable. The paper also reported that retrospective analysis of millions of patient records confirmed higher survival among cancer patients using sildenafil, with an even stronger benefit when statins were co‑administered.

On 1 August 2026, the same research team reiterated these findings, noting that the National Cancer Institute highlighted the repurposing approach as promising but stressed that the results remain experimental. All authors continue to call for rigorous clinical trials before sildenafil could be considered a therapeutic option for cancer patients.

Claims

What the coverage asserts, and how well corroborated each claim is across sources.

[● 7 SOURCES] Researchers identified a mechanism by which sildenafil can inhibit cancer cell metastasis. (Weizmann Institute study)
[● 7 SOURCES] Sildenafil inhibits phosphodiesterase type 5 (PDE5), raising intracellular cGMP levels. (Weizmann Institute study)
[● 7 SOURCES] Elevated cGMP interferes with NPC1 protein, reducing cholesterol transport in tumor cells. (Weizmann Institute study)
[● 7 SOURCES] Reduced cholesterol availability hampers tumor cell migration and metastasis formation. (Weizmann Institute study)
[● 7 SOURCES] The anti‑metastatic effect is enhanced when sildenafil is combined with statins. (Weizmann Institute study)
[● 7 SOURCES] Laboratory tests on animal and human tumor cells showed increased susceptibility to sildenafil‑induced metabolic disruption. (Weizmann Institute study)
[● 7 SOURCES] Retrospective clinical data indicated higher survival rates for cancer patients who used sildenafil, especially with statins. (Weizmann Institute study)
[● 7 SOURCES] The study was conducted by the Weizmann Institute of Science in Israel with U.S. researchers and published in Cancer Research. (Weizmann Institute study)
[● 3 SOURCES] Further pre‑clinical studies and clinical trials are required before sildenafil can be used as a cancer therapy. (Researchers at the Weizmann Institute of Science)

Timeline

about 19 hours ago

[HEALTH] 2 sources
Sildenafil blocks cancer metastasis in preclinical study
A preclinical study by the Weizmann Institute and US partners shows sildenafil may hinder cancer metastasis by blocking tumor cholesterol use, but clinical trials are still needed.
3 days ago

[HEALTH] 7 sources
Weizmann Institute study finds Viagra may block cancer metastasis
Weizmann Institute researchers report that Viagra (sildenafil) blocks tumor cholesterol transport, reducing metastasis in lab studies and linking to higher survival in patients, especially with statins.
8 days ago

[HEALTH] 4 sources
Viagra's active ingredient shows potential to block cancer metastasis
Weizmann Institute researchers report sildenafil (Viagra) blocks a cholesterol‑related pathway, reducing cancer cell spread in labs and improving survival in Israeli patient data, but clinical trials are needed
11 days ago

[HEALTH] 7 sources
Viagra (sildenafil) may block cancer metastasis in preclinical research
US‑Israel researchers found sildenafil may hinder cancer metastasis in mouse models by disrupting cholesterol transport, especially when paired with statins.

Sources

brasilemfolhas.com · deultimominuto.net · dol.com.br · ensegundos.do · fehmarn24.de · katalogfirm.pl · knowridge.com · kopalniawiedzy.pl · kurierverlag.de · leinetal24.de · mag.newsweek.com · multimediosprisma.com · oglobo.globo.com · orienteeringonline.net · santiago30caballeros.com · sintinta.com.ar · tessenderlo.com · tribunaonline.com.br · xeu.com.mx · xeu.mx

This summary has been updated 5 times: see revision history